CytomX Therapeutics Inc (NASDAQ: CTMX)’s stock price has increased by 157.06 compared to its previous closing price of 1.63. However, the company has seen a 157.06% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-05-01 that – CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study –
Is It Worth Investing in CytomX Therapeutics Inc (NASDAQ: CTMX) Right Now?
Additionally, the 36-month beta value for CTMX is 1.08. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTMX is 66.47M and currently, short sellers hold a 5.41% ratio of that float. The average trading volume of CTMX on May 01, 2024 was 928.95K shares.
CTMX’s Market Performance
CTMX stock saw an increase of 157.06% in the past week, with a monthly gain of 95.79% and a quarterly increase of 173.86%. The volatility ratio for the week is 4.27%, and the volatility levels for the last 30 days are 5.86% for CytomX Therapeutics Inc (CTMX). The simple moving average for the last 20 days is 125.51% for CTMX stock, with a simple moving average of 162.12% for the last 200 days.
Analysts’ Opinion of CTMX
BMO Capital Markets, on the other hand, stated in their research note that they expect to see CTMX reach a price target of $2.60, previously predicting the price at $3. The rating they have provided for CTMX stocks is “Market Perform” according to the report published on November 14th, 2022.
Wedbush gave a rating of “Neutral” to CTMX, setting the target price at $2 in the report published on July 07th of the previous year.
CTMX Trading at 104.51% from the 50-Day Moving Average
After a stumble in the market that brought CTMX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 46.76% of gains for the given period.
Volatility was left at 5.86%, however, over the last 30 days, the volatility rate increased by 4.27%, as shares surge +142.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +254.08% upper at present.
During the last 5 trading sessions, CTMX rose by +219.33%, which changed the moving average for the period of 200-days by +178.34% in comparison to the 20-day moving average, which settled at $2.0108. In addition, CytomX Therapeutics Inc saw 170.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTMX starting from McCarthy Sean A., who sale 20,223 shares at the price of $2.09 back on Mar 19 ’24. After this action, McCarthy Sean A. now owns 524,481 shares of CytomX Therapeutics Inc, valued at $42,175 using the latest closing price.
BELVIN MARCIA, the SVP, Chief Scientific Officer of CytomX Therapeutics Inc, sale 12,795 shares at $2.09 during a trade that took place back on Mar 19 ’24, which means that BELVIN MARCIA is holding 168,579 shares at $26,684 based on the most recent closing price.
Stock Fundamentals for CTMX
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.95 for the gross margin
The net margin for CytomX Therapeutics Inc stands at 0.02. The total capital return value is set at -0.13.
Based on CytomX Therapeutics Inc (CTMX), the company’s capital structure generated -0.42 points at debt to capital in total, while cash flow to debt ratio is standing at -4.01. The debt to equity ratio resting at -0.29. The interest coverage ratio of the stock is 2.77.
Currently, EBITDA for the company is -4.31 million with net debt to EBITDA at 0.67. When we switch over and look at the enterprise to sales, we see a ratio of 3.04. The receivables turnover for the company is 29.49for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
In conclusion, CytomX Therapeutics Inc (CTMX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
